Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
December 31, 2025 0.6446M
September 30, 2025 0.6211M
June 30, 2025 0.6211M
March 31, 2025 0.6018M
December 31, 2024 0.6196M
September 30, 2024 11.37M
June 30, 2024 7.642M
March 31, 2024 7.642M
December 31, 2023 7.666M
September 30, 2023 7.642M
June 30, 2023 7.642M
March 31, 2023 7.622M
December 31, 2022 0.254M
September 30, 2022 0.254M
June 30, 2022 0.254M
March 31, 2022 4.180M
December 31, 2021 4.180M
September 30, 2021 0.1393M
June 30, 2021 4.180M
March 31, 2021 4.180M
December 31, 2020 4.180M
September 30, 2020 4.180M
June 30, 2020 4.180M
March 31, 2020 4.101M
December 31, 2019 4.180M
Date Value
September 30, 2019 4.180M
June 30, 2019 4.180M
March 31, 2019 4.180M
December 31, 2018 4.180M
September 30, 2018 4.101M
June 30, 2018 4.101M
March 31, 2018 4.101M
December 31, 2017 4.186M
September 30, 2017 4.101M
June 30, 2017 4.101M
March 31, 2017 4.101M
December 31, 2016 4.621M
September 30, 2016 4.101M
June 30, 2016 4.101M
March 31, 2016 4.660M
December 31, 2015 4.660M
September 30, 2015 4.743M
June 30, 2015 4.743M
March 31, 2015 4.450M
December 31, 2014 4.584M
September 30, 2014 4.101M
June 30, 2014 4.101M
March 31, 2014 4.101M
December 31, 2013 4.483M
September 30, 2013 4.101M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
DBV Technologies SA 59.18M
Cellectis SA 100.70M
Akari Therapeutics Plc 1.750M
Autolus Therapeutics Plc 266.16M
Evaxion AS 8.340M